Management of Advanced Small Bowel Cancer

Alberto Puccini, Francesca Battaglin, Heinz-Josef Lenz

Research output: Contribution to journalReview articlepeer-review


OPINION STATEMENT: Small bower cancer is a rare disease, despite its incidence is increasing in the last decade. Both benign and malignant tumors can arise from the small intestine. The main histological cancer types are adenocarcinomas, neuroendocrine tumors, sarcomas, gastrointestinal stromal tumors (GISTs), and lymphomas. Due to the rarity of these malignances, all the currently available data are based on small studies or retrospective series, although recent breakthroughs are redirecting our approach to these patients. Immunotherapy for small bowel adenocarcinomas, several multikinase inhibitors in resistant GIST patients, as well as everolimus and 177Lu-DOTATATE in neuroendocrine tumors are only few of the novel therapeutic options that have changed, or may change in the future, the therapeutic landscape of these rare cancers. Larger and more powerful studies on the molecular profile of these tumors may lead to a better design of clinical trials, which eventually would provide our patients with more efficacious treatments to improve both overall survival and quality of life.

Original languageEnglish
Pages (from-to)69
JournalCurrent Treatment Options in Oncology
Issue number12
Publication statusPublished - Nov 5 2018


Dive into the research topics of 'Management of Advanced Small Bowel Cancer'. Together they form a unique fingerprint.

Cite this